MAPT and early-onset autosomal dominant Alzheimer disease: In this context, doxazosin showed neuroprotective effects in an in vitro model of Alzheimer's disease characterized by increased Akt activity, reduced phosphorylation of Tau proteins, and reduced neurotoxic effects of β-amyloids on hippocampal slices [20].